FDA OKs Blueprint kinase inhibitor for GI tumor

The FDA approves Blueprint Medicines’ (BPMC +0.9%) Ayvakit (avapritinib) for the treatment of adults with unresectable/metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha ((PDGFRA)) exon 18 mutation, including PDGFRA D842V-positive GIST, the most common exon 18 mutation.

Avapritinib is an oral inhibitor of KIT- and PDGFRA-mutant kinases which are highly active in GIST.

https://seekingalpha.com/news/3530801-fda-oks-blueprint-kinase-inhibitor-for-gi-tumor